OrbiMed

OrbiMed
Name	OrbiMed
Type	Private
Industry	Private equity, Venture capital, Biotechnology industry
Founded	1989
Headquarters	New York City
Key people	Samuel D. Isaly; Jean-Marc Huet; Sana Khareghani
Products	Investment funds; asset management

OrbiMed OrbiMed is a global investment firm focused on the Healthcare industry, Biotechnology industry, Pharmaceutical industry, and Medical device sectors. Founded in 1989, the firm has offices in major financial and scientific centers and invests across private equity, venture capital, and public markets. OrbiMed has participated in seed, growth, buyout, and crossover financings for companies and has relationships with universities, research institutes, and multinational corporations.

History

OrbiMed was founded in 1989 in New York City by professionals who previously worked at large investment firms and asset managers with exposure to Pharmaceutical industry portfolios. In the 1990s the firm expanded during waves of consolidation in the Pharmaceutical industry and the rise of Biotechnology industry financings associated with research at institutions like Harvard University, Massachusetts Institute of Technology, Stanford University, and University of California, San Francisco. During the 2000s OrbiMed opened offices in San Francisco, London, Mumbai, Shanghai, and Tel Aviv to follow regional innovation clusters such as Silicon Valley, Cambridge, Massachusetts, Biocon, and Teva Pharmaceutical Industries. The firm has been active through market cycles including the Dot-com bubble downturn and the 2008 Global financial crisis, participating in crossover rounds that connected private companies to public markets such as listings on the New York Stock Exchange and NASDAQ.

Business model and investment strategies

OrbiMed operates as an asset manager deploying capital through sector-specific funds that target companies at different stages: early-stage Venture capital rounds, growth equity, buyouts, and public equities focused on healthcare. The firm sources deals from academic spinouts at institutions like Johns Hopkins University, Columbia University, University of Pennsylvania, and Yale University and from corporate collaborations with firms like Johnson & Johnson, Pfizer, Roche, Novartis, and GlaxoSmithKline. Investment strategies include concentrated private placements, crossover financing ahead of initial public offerings on exchanges such as NYSE American and NASDAQ, PIPE transactions related to firms like Moderna and Regeneron Pharmaceuticals, and secondary purchases from limited partners including Pension Benefit Guaranty Corporation-backed funds and sovereign wealth funds. Portfolio construction emphasizes therapeutic pipelines, regulatory pathways involving agencies like the U.S. Food and Drug Administration and the European Medicines Agency, reimbursement considerations with payers such as Centers for Medicare & Medicaid Services, and intellectual property landscapes involving patent filers like Genentech and Amgen.

Funds and notable investments

OrbiMed has launched multiple fund types, including dedicated private equity funds, public long/short funds, and regionally focused vehicles targeting China and India. Notable private investments and public positions have included companies and institutions such as Illumina, Gilead Sciences, Vertex Pharmaceuticals, Alexion Pharmaceuticals, Alnylam Pharmaceuticals, Biogen, Thermo Fisher Scientific, Intuitive Surgical, CRISPR Therapeutics, Editas Medicine, Bluebird Bio, Sarepta Therapeutics, Ionis Pharmaceuticals, Regeneron Pharmaceuticals, Moderna, Roche, Novartis, Amgen, Pfizer, Johnson & Johnson, Bristol-Myers Squibb, Eli Lilly and Company, Sanofi, Takeda Pharmaceutical Company, AstraZeneca, GSK plc, Teva Pharmaceutical Industries, Mylan (now part of Viatris), Biocon, Dr. Reddy's Laboratories, Zydus Cadila, Hoffmann-La Roche, Shanghai Pharmaceuticals, Sinopharm, Samsung Biologics, CureVac, Sarepta Therapeutics, Catalent, Charles River Laboratories, Covance (LabCorp) and spinouts from Cold Spring Harbor Laboratory, Broad Institute, and Salk Institute.

Organizational structure and leadership

OrbiMed’s leadership comprises investment professionals with backgrounds at firms such as Goldman Sachs, J.P. Morgan, Morgan Stanley, BlackRock, TPG Capital, Bain Capital, KKR, and Sequoia Capital. The firm’s regional offices report to global investment committees modeled on governance used by institutions like Harvard Management Company and Yale Investments Office. Compensation and carried interest structures align partners and limited partners similar to frameworks used at Andreessen Horowitz, NEA, and Accel Partners. OrbiMed has recruited scientific advisers from academic centers including Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, and biotech companies such as Genentech and Amgen.

Financial performance and fundraising

OrbiMed has raised multiple flagship funds and sidecars, attracting commitments from limited partners such as Pension funds like CalPERS, university endowments like Yale Endowment and Harvard Endowment, family offices, and sovereign investors including Government of Singapore Investment Corporation and Abu Dhabi Investment Authority. Fund sizes have ranged from hundreds of millions to several billion dollars, and the firm reports returns benchmarked against indices such as the NASDAQ Biotechnology Index and the S&P 500. OrbiMed’s public equity strategies have delivered concentrated bets that outperformed peers during biotech rallies, while private funds have realized exits via public offerings and acquisitions by corporations including Pfizer, Roche, Novartis, and Johnson & Johnson.

Controversies and legal matters

OrbiMed has been subject to scrutiny typical for large asset managers including regulatory inquiries and litigation related to trading, disclosure practices, and personnel matters comparable to cases involving firms like Citadel LLC and Point72 Asset Management. The firm has navigated conflicts of interest concerns arising from crossover investing, relationships with corporate partners, and board seats in portfolio companies — issues that have drawn attention in regulatory contexts involving the U.S. Securities and Exchange Commission, Financial Conduct Authority (UK), and stock exchange listing rules on NASDAQ and New York Stock Exchange. OrbiMed has also addressed reputational matters linked to partner departures and contested governance decisions similar to disputes publicized at Valeant Pharmaceuticals International and Theranos-adjacent controversies.

Category:Private equity firms Category:Venture capital firms Category:Financial services companies of the United States